Elena Nikulina

Ocugen to present 3Q 2026 financial results on November 4

Ocugen to present 3Q 2026 financial results on November 4
Ocugen to release Q3 results

Ocugen has announced it will release its third quarter 2026 financial results on Wednesday, November 4, at 8:30 a.m. Eastern Time.

The company will host a conference call and webcast to provide a business update and discuss its latest financial performance. Investors can access further details through the provided webcast link in the announcement.

Ocugen recently signed an OCU400 licensing agreement with Roots Pharmaceutical for the MENA region, valued at up to $259 million in milestones and royalties, according to a previous announcement. The company has also advanced its OCU410 gene therapy for geographic atrophy into a Phase 3 clinical trial, as reported earlier. These developments come as Ocugen prepares to share its third quarter 2026 financial results.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.